Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses

Lignende værker

• Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non–Small Cell Lung Cancer Trials: A Meta-analysis
  af: Blumenthal, Gideon M., et al.
  Udgivet: (2017)
• Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non–Small Cell Lung Cancer
  af: Kazandjian, Dickran, et al.
  Udgivet: (2019)
• US Food and Drug Administration Approval Overview in Metastatic Breast Cancer
  af: Cortazar, Patricia, et al.
  Udgivet: (2012)
• FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
  af: Kazandjian, Dickran, et al.
  Udgivet: (2016)
• FDA Approval Summary: Sunitinib for the Treatment of Progressive Well-Differentiated Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors
  af: Blumenthal, Gideon M., et al.
  Udgivet: (2012)